A Study to Evaluate the Long-term Safety of HS-10380 in Patients With Schizophrenia

The primary purpose of this open-label phase 3 study is to evaluate the safety of HS-10380 on the incidence, severity, relationship to investigational product of adverse events (AE), serious adverse events (SAE), and adverse events leading to study drug discontinuationin Chinese adult participants with schizophrenia.

NCT Number	NCT07759869
Lead Sponsor	Jiangsu Hansoh Pharmaceutical Co., Ltd.
Conditions	SCHIZOPHRENIA 1 (Disorder)
Enrollment	500 participants
Start Date	2026-09-09
Primary Completion	2028-07-31 (estimated)
Study Completion	2028-08-31 (estimated)
Updated on ClinicalTrials.gov	2026-08-12